$90.73
-1.53[-1.66%]
At close: Apr 25
$90.73
0[0.00%]
After Hours: 4:20PM EDT
Blueprint Medicines
(NASDAQ:BPMC)Blueprint Medicines Stock (NASDAQ:BPMC), Analyst Ratings, Price Targets, Predictions
Blueprint Medicines Corp has a consensus price target of $88.09, established from looking at the 100 latest analyst ratings. The last 3 analyst ratings were released from JMP Securities, Needham, and JMP Securities on April 10, 2024, February 26, 2024, and February 16, 2024. With an average price target of $108.33 between JMP Securities, Needham, and JMP Securities, there's an implied 19.40% upside for Blueprint Medicines Corp from these 3 analyst ratings.
Analyst Firms Making Recommendations1
JMP Securities
Needham
Citigroup
Barclays
Stifel
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Blueprint Medicines
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/10/2024 | BPMC | Buy Now | Blueprint Medicines | $90.73 | 25.65% | JMP Securities | Reni Benjamin | → $114 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/26/2024 | BPMC | Buy Now | Blueprint Medicines | $90.73 | 6.91% | Needham | Ami Fadia | → $97 | Reiterates | Buy → Buy | Get Alert |
| 02/16/2024 | BPMC | Buy Now | Blueprint Medicines | $90.73 | 25.65% | JMP Securities | Reni Benjamin | → $114 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/16/2024 | BPMC | Buy Now | Blueprint Medicines | $90.73 | -28.36% | Citigroup | David Lebowitz | $54 → $65 | Maintains | Sell | Get Alert |
| 02/13/2024 | BPMC | Buy Now | Blueprint Medicines | $90.73 | -22.85% | Barclays | Peter Lawson | $58 → $70 | Maintains | Equal-Weight | Get Alert |
| 01/16/2024 | BPMC | Buy Now | Blueprint Medicines | $90.73 | 25.65% | JMP Securities | Reni Benjamin | → $114 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 01/09/2024 | BPMC | Buy Now | Blueprint Medicines | $90.73 | 6.91% | Stifel | Bradley Canino | $95 → $97 | Maintains | Buy | Get Alert |
| 12/22/2023 | BPMC | Buy Now | Blueprint Medicines | $90.73 | 10.22% | Raymond James | Dane Leone | $85 → $100 | Maintains | Strong Buy | Get Alert |
| 12/19/2023 | BPMC | Buy Now | Blueprint Medicines | $90.73 | 26.75% | Wells Fargo | Derek Archila | $86 → $115 | Maintains | Overweight | Get Alert |
| 12/11/2023 | BPMC | Buy Now | Blueprint Medicines | $90.73 | -6.32% | HC Wainwright & Co. | Andrew Fein | → $85 | Reiterates | Buy → Buy | Get Alert |
| 10/27/2023 | BPMC | Buy Now | Blueprint Medicines | $90.73 | -6.32% | Oppenheimer | Matthew Biegler | → $85 | Upgrade | Perform → Outperform | Get Alert |
| 10/27/2023 | BPMC | Buy Now | Blueprint Medicines | $90.73 | -30.56% | Morgan Stanley | Michael Ulz | $59 → $63 | Maintains | Equal-Weight | Get Alert |
| 10/27/2023 | BPMC | Buy Now | Blueprint Medicines | $90.73 | -36.07% | Barclays | Peter Lawson | $46 → $58 | Maintains | Equal-Weight | Get Alert |
| 10/27/2023 | BPMC | Buy Now | Blueprint Medicines | $90.73 | -18.44% | Needham | Ami Fadia | $66 → $74 | Maintains | Buy | Get Alert |
| 08/21/2023 | BPMC | Buy Now | Blueprint Medicines | $90.73 | -27.26% | Needham | Ami Fadia | $65 → $66 | Maintains | Buy | Get Alert |
| 08/07/2023 | BPMC | Buy Now | Blueprint Medicines | $90.73 | 25.65% | JMP Securities | Reni Benjamin | → $114 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 08/03/2023 | BPMC | Buy Now | Blueprint Medicines | $90.73 | -34.97% | Morgan Stanley | Michael Ulz | $55 → $59 | Maintains | Equal-Weight | Get Alert |
| 08/03/2023 | BPMC | Buy Now | Blueprint Medicines | $90.73 | -8.52% | Goldman Sachs | Terence Flynn | $93 → $83 | Maintains | Buy | Get Alert |
| 08/03/2023 | BPMC | Buy Now | Blueprint Medicines | $90.73 | -28.36% | Needham | Ami Fadia | → $65 | Reiterates | Buy → Buy | Get Alert |
FAQ
What is the target price for Blueprint Medicines (BPMC)?
The latest price target for Blueprint Medicines (NASDAQ: BPMC) was reported by JMP Securities on April 10, 2024. The analyst firm set a price target for $114.00 expecting BPMC to rise to within 12 months (a possible 25.65% upside). 36 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Blueprint Medicines (BPMC)?
The latest analyst rating for Blueprint Medicines (NASDAQ: BPMC) was provided by JMP Securities, and Blueprint Medicines reiterated their market outperform rating.
When was the last upgrade for Blueprint Medicines (BPMC)?
The last upgrade for Blueprint Medicines Corp happened on October 27, 2023 when Oppenheimer raised their price target to $85. Oppenheimer previously had a perform for Blueprint Medicines Corp.
When was the last downgrade for Blueprint Medicines (BPMC)?
The last downgrade for Blueprint Medicines Corp happened on June 5, 2023 when SVB Leerink changed their price target from $48 to $43 for Blueprint Medicines Corp.
When is the next analyst rating going to be posted or updated for Blueprint Medicines (BPMC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Blueprint Medicines, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Blueprint Medicines was filed on April 10, 2024 so you should expect the next rating to be made available sometime around April 10, 2025.
Is the Analyst Rating Blueprint Medicines (BPMC) correct?
While ratings are subjective and will change, the latest Blueprint Medicines (BPMC) rating was a reiterated with a price target of $0.00 to $114.00. The current price Blueprint Medicines (BPMC) is trading at is $90.73, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.